BioWorld MedTech

Aug. 24, 2016

View Archived Issues

Iglarlixi delay puts more eyes on PRVs as business tool

Clinical utility still a major hurdle for potential coverage of novel diagnostics

Mylan tries to deflect public shaming on social media over the cost of Epipen

Daily M&A

Appointments and advancements

Other news to note

Product briefs

MDD's Oncology Extra

Lengthy MDUFA talks yield tentative agreement between FDA, industry

Three entities representing the medical device and imaging communities are heralding a tentative agreement with the FDA for the fourth reauthorization of a medical device user fee program. Read More

FDA a good sport, clears first concussion-specific computerized tests

Today's news in brief

BioWorld

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

SERCA inhibitor from Sumitomo shows promise for MSA-C treatment

BioWorld Science

At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....